ECSP11011553A - Nuevos conjugados, su preparación y su aplicación terapéutica - Google Patents
Nuevos conjugados, su preparación y su aplicación terapéuticaInfo
- Publication number
- ECSP11011553A ECSP11011553A EC2011011553A ECSP11011553A ECSP11011553A EC SP11011553 A ECSP11011553 A EC SP11011553A EC 2011011553 A EC2011011553 A EC 2011011553A EC SP11011553 A ECSP11011553 A EC SP11011553A EC SP11011553 A ECSP11011553 A EC SP11011553A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- alkyl
- alkyl group
- phenyl nucleus
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a un agente de selección de la diana al que está unido al menos un derivado de criptoficina de la fórmula (I), en la que: R1 representa un átomo de halógeno y R2 representa un grupo -OH, un grupo acilo derivado de un aminoácido AA o un grupo alcanoiloxi(C1-C4); o bien R1 y R2 forman conjuntamente un motivo epóxido; AA indica un aminoácido natural o no natural; R3 representa un grupo alquilo(C1-C6); R4 y R5 representan los dos H o forman conjuntamente un doble enlace CH=CH entre C13 y C14; R6 y R7 representan independientemente uno de otro H o un grupo alquilo(C1-C6); R8 y R9 representan independientemente uno de otro H o un grupo alquilo(C1-C6); R10 representa al menos un sustituyente del núcleo fenilo elegido entre: H, un grupo OH, alcoxi(C1-C4), un átomo de halógeno o bien un grupo -NH2, -NHalquilo(C1-C6) o N(alquilo(C1-C6))2; R11 representa al menos un sustituyente del núcleo fenilo elegido entre H o un grupo alquilo(C1-C4); estando unidos el agente de selección de la diana y el derivado de criptoficina de forma covalente, situándose la unión en posición orto (o), meta (m) o para (p) del núcleo fenilo
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0903170A FR2947269B1 (fr) | 2009-06-29 | 2009-06-29 | Nouveaux composes anticancereux |
| FR0905651A FR2947271B1 (fr) | 2009-06-29 | 2009-11-25 | Nouveaux composes anticancereux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011553A true ECSP11011553A (es) | 2012-01-31 |
Family
ID=41611078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011553A ECSP11011553A (es) | 2009-06-29 | 2011-12-26 | Nuevos conjugados, su preparación y su aplicación terapéutica |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8952147B2 (es) |
| EP (1) | EP2448929A1 (es) |
| JP (1) | JP5746692B2 (es) |
| KR (1) | KR101770584B1 (es) |
| CN (1) | CN102482238B (es) |
| AR (1) | AR078131A1 (es) |
| BR (1) | BRPI1015131A2 (es) |
| CA (1) | CA2766762C (es) |
| CL (1) | CL2011003229A1 (es) |
| CO (1) | CO6430462A2 (es) |
| CR (1) | CR20110670A (es) |
| DO (1) | DOP2011000376A (es) |
| EA (1) | EA024627B1 (es) |
| EC (1) | ECSP11011553A (es) |
| FR (2) | FR2947269B1 (es) |
| HN (1) | HN2011003414A (es) |
| IL (1) | IL217208A (es) |
| MA (1) | MA33465B1 (es) |
| MX (1) | MX2011013764A (es) |
| MY (1) | MY156684A (es) |
| NI (1) | NI201100219A (es) |
| NZ (1) | NZ597136A (es) |
| PE (1) | PE20121031A1 (es) |
| SG (2) | SG10201607595WA (es) |
| SV (1) | SV2011004086A (es) |
| TN (1) | TN2011000636A1 (es) |
| TW (1) | TW201110986A (es) |
| UY (1) | UY32745A (es) |
| WO (1) | WO2011001052A1 (es) |
| ZA (1) | ZA201109537B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| EP2437790B1 (en) | 2009-06-03 | 2019-02-20 | Immunogen, Inc. | Conjugation methods |
| EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| TR201902180T4 (tr) | 2011-03-29 | 2019-03-21 | Immunogen Inc | Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi |
| UA121539C2 (uk) | 2011-09-02 | 2020-06-25 | Інсайт Холдинґс Корпорейшн | Гетероцикліламіни як інгібітори рі3к |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| RU2661083C2 (ru) | 2012-10-04 | 2018-07-11 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент |
| HRP20170743T1 (hr) | 2012-11-20 | 2017-07-28 | Sanofi | Anti-ceacam5 protutijela i njihova uporaba |
| BR112016000585A2 (pt) | 2013-07-11 | 2018-03-20 | Novartis Ag | modificações quimioenzimáticas sítio-específicas de proteína |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| PT3189056T (pt) * | 2014-09-03 | 2020-09-04 | Immunogen Inc | Derivados citotóxicos de benzodiazepina |
| GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
| UA122332C2 (uk) | 2015-02-27 | 2020-10-26 | Інсайт Корпорейшн | Солі інгібітора pi3k і способи їх отримання |
| EP3069734A1 (en) * | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| CN107029242A (zh) | 2015-11-03 | 2017-08-11 | 财团法人工业技术研究院 | 抗体药物复合物及其制造方法 |
| TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| WO2017136769A1 (en) * | 2016-02-04 | 2017-08-10 | Eisai R&D Management Co., Ltd. | Peptide drug conjugates |
| AU2016429272A1 (en) | 2016-11-14 | 2019-05-02 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
| AU2018265333C1 (en) | 2017-05-10 | 2025-04-24 | Sanofi | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
| WO2019030284A1 (en) | 2017-08-09 | 2019-02-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF |
| AU2018389100B2 (en) * | 2017-12-22 | 2025-02-27 | Cornell University | 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
| WO2021067460A1 (en) | 2019-09-30 | 2021-04-08 | The Regents Of The University Ofmichigan | Biocatalytic synthesis of cryptophycin anticancer agents |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US12564642B2 (en) | 2020-11-10 | 2026-03-03 | Sanofi | CEACAM5 antibody-drug conjugate formulation |
| EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024536382A (ja) | 2021-10-07 | 2024-10-04 | サノフイ | イミダゾ［４，５－ｃ］キノリン－４－アミン化合物及びそのコンジュゲート、それらの調製並びにそれらの治療用途 |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| KR20260046445A (ko) | 2023-08-04 | 2026-04-07 | 사노피 | 이미다조[4,5-d]피리다진 화합물 및 이의 접합체, 이의 제조 및 이의 치료적 적용 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2719170A (en) | 1954-07-28 | 1955-09-27 | Du Pont | Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters |
| US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
| FI913049A0 (fi) | 1988-12-22 | 1991-06-20 | Xoma Corp | Foerhindrande kopplingsmedel och foerfaranden. |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2056039A1 (en) | 1991-01-22 | 1992-07-23 | Philip L. Fuchs | Carbacyclin analogs |
| AU723652B2 (en) | 1993-12-21 | 2000-08-31 | University Of Hawaii | New cryptophycins from synthesis |
| CA2264063C (en) * | 1996-08-30 | 2007-03-13 | Eli Lilly And Company | Cryptophycin compounds |
| AU1123200A (en) | 1998-10-16 | 2000-05-08 | Eli Lilly And Company | Stereoselective process for producing antineoplastic agents |
| WO2000034252A2 (en) | 1998-12-07 | 2000-06-15 | Eli Lilly And Company | Process for the preparation of cryptophycin derivatives |
| JP2005511627A (ja) * | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス，インコーポレーテッド | 抗ｃｄ３０抗体を使用する免疫学的疾患の治療 |
| US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| ES2361739T3 (es) | 2002-08-16 | 2011-06-21 | Immunogen, Inc. | Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña. |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| HUE026914T2 (en) | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| KR101145506B1 (ko) | 2003-05-20 | 2012-05-15 | 이뮤노젠 아이엔씨 | 새로운 메이탠시노이드를 포함하는 개선된 세포독성체 |
| KR101672664B1 (ko) | 2003-07-21 | 2016-11-04 | 이뮤노젠 아이엔씨 | 인간화된 항체 또는 그의 항원결정기 결합절편 |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| SV2006002258A (es) | 2004-10-08 | 2006-09-19 | Wyeth Corp | Inmunoterapia de trastornos autoinmunes |
| EP1669358A1 (en) | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
| PL1819359T3 (pl) * | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
| CA2600418A1 (en) | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
| WO2007127440A2 (en) | 2006-04-27 | 2007-11-08 | Intezyne Technologies, Inc. | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
| EA020324B1 (ru) | 2006-07-18 | 2014-10-30 | Санофи-Авентис | АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN104383553A (zh) * | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| KR101674097B1 (ko) | 2008-04-11 | 2016-11-08 | 시애틀 지네틱스, 인크. | 췌장, 난소 및 다른 암의 검출 및 치료 |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| EP2281006B1 (en) | 2008-04-30 | 2017-08-02 | Immunogen, Inc. | Cross-linkers and their uses |
| WO2010014812A2 (en) | 2008-07-30 | 2010-02-04 | The Research Foundation Of State University Of New York | Peptide compositions and methods of use |
-
2009
- 2009-06-29 FR FR0903170A patent/FR2947269B1/fr not_active Expired - Fee Related
- 2009-11-25 FR FR0905651A patent/FR2947271B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-20 EA EA201270096A patent/EA024627B1/ru not_active IP Right Cessation
- 2010-05-20 JP JP2012518108A patent/JP5746692B2/ja not_active Expired - Fee Related
- 2010-05-20 BR BRPI1015131-1A patent/BRPI1015131A2/pt not_active Application Discontinuation
- 2010-05-20 KR KR1020117031276A patent/KR101770584B1/ko not_active Expired - Fee Related
- 2010-05-20 MY MYPI2011006289A patent/MY156684A/en unknown
- 2010-05-20 MA MA34580A patent/MA33465B1/fr unknown
- 2010-05-20 CN CN201080038575.2A patent/CN102482238B/zh not_active Expired - Fee Related
- 2010-05-20 SG SG10201607595WA patent/SG10201607595WA/en unknown
- 2010-05-20 NZ NZ597136A patent/NZ597136A/en not_active IP Right Cessation
- 2010-05-20 CA CA2766762A patent/CA2766762C/fr not_active Expired - Fee Related
- 2010-05-20 PE PE2011002178A patent/PE20121031A1/es not_active Application Discontinuation
- 2010-05-20 WO PCT/FR2010/050986 patent/WO2011001052A1/fr not_active Ceased
- 2010-05-20 MX MX2011013764A patent/MX2011013764A/es active IP Right Grant
- 2010-05-20 EP EP10728799A patent/EP2448929A1/fr not_active Withdrawn
- 2010-05-20 SG SG2011097193A patent/SG177419A1/en unknown
- 2010-06-28 TW TW099121094A patent/TW201110986A/zh unknown
- 2010-06-28 AR ARP100102290A patent/AR078131A1/es unknown
- 2010-06-29 UY UY0001032745A patent/UY32745A/es not_active Application Discontinuation
-
2011
- 2011-12-05 DO DO2011000376A patent/DOP2011000376A/es unknown
- 2011-12-12 TN TNP2011000636A patent/TN2011000636A1/fr unknown
- 2011-12-13 CR CR20110670A patent/CR20110670A/es unknown
- 2011-12-15 SV SV2011004086A patent/SV2011004086A/es unknown
- 2011-12-19 NI NI201100219A patent/NI201100219A/es unknown
- 2011-12-20 CL CL2011003229A patent/CL2011003229A1/es unknown
- 2011-12-20 US US13/331,259 patent/US8952147B2/en not_active Expired - Fee Related
- 2011-12-23 ZA ZA2011/09537A patent/ZA201109537B/en unknown
- 2011-12-26 EC EC2011011553A patent/ECSP11011553A/es unknown
- 2011-12-26 IL IL217208A patent/IL217208A/en not_active IP Right Cessation
- 2011-12-28 HN HN2011003414A patent/HN2011003414A/es unknown
- 2011-12-29 CO CO11180696A patent/CO6430462A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6430462A2 (es) | Nuevos conjugados, su preparación y su aplicación terapéutica | |
| PE20090211A1 (es) | Inhibidores de las iap | |
| EA201171328A1 (ru) | Производное замещенного изохинолина | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| NZ621981A (en) | Lipid compositions | |
| AR061974A1 (es) | Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion | |
| CO6351789A2 (es) | Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica | |
| AR010743A1 (es) | Compuestos de pirazol, utiles como inhibidores de la liberacion de acidos grasos mediada por la fosfolipasa a2 secretora no pancreatica humana.procedimientos para preparar dichos compuestos y composiciones farmaceuticas formuladas con dichos compuestos | |
| CY1111601T1 (el) | Παραγωγα καρβοξαμιδιων της τριαζολοπυριδινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| AR058077A1 (es) | Derivados de acidos fenoxiaceticos | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| EA201070010A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
| BR112013001534A2 (pt) | derivados de oxadiazol e piridazina, suas preparações e suas aplicações em terapêutica | |
| CO6290668A2 (es) | Derivados de 1-oxo-1,2-dihidroisoquinolein-5-carboxamidas y de 4-oxo-3,4-dihifroquinazolina -8-carboxamidas su preparacion y su aplicacion en terapeutica | |
| AR069643A1 (es) | Derivados diazenidiolatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| BR112013007145A2 (pt) | composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável | |
| EA200970399A1 (ru) | Производные тетрагидронафталин-1-карбоновой кислоты, ингибирующие мтр | |
| AR046212A1 (es) | Derivados de 2-fenilbenzofurano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| CU20120041A7 (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR074629A1 (es) | Derivados de 1-bencil-cinolin-4-(1h)-ona sustituidos, su preparacion, composiciones farmaceuticas y su uso en el tratamiento de patologias asociadas con receptores de los cannabinoides cb2 | |
| AR076205A1 (es) | Derivados de 1-alquil-cinolin-4(1h)-ona, su preparacion, composicion farmaceutica y su uso para tratar patologias en la que esten implicados receptores de cannabinoides cb2 | |
| JP2013001660A5 (es) | ||
| UA108473C2 (uk) | Кон'югати, їхнє одержання і застосування в терапії |